67 results about "Regulatory peptide" patented technology

The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a gene-regulatory peptide. The invention provides a pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from disease, the pharmaceutical composition comprising a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.

The invention discloses bifidobacterium bifidum capable of remarkably relieving constipation and application thereof and belongs to the technical field of microorganisms. The bifidobacterium bifidum CGMCC NO.13632 can well tolerate simulative gastrointestinal fluid, can be well attached to colon cancer cells HT-29, and can remarkably increase the water content of excrement of constipation mice and shorten the first tarry stool time. On the aspect of increasing the small intestine driving rate, the bifidobacterium bifidum CGMCC NO.13632 is superior to cathartic phenolphthalein, a best effect is shown, secretion of gastrointestinal regulatory peptide relevant to constipation in serum is also adjusted while constipation pathological factors are remarkably improved, and the bifidobacterium bifidum does not have toxic and side effects of medicine for treating constipation, and is a first choice for preventing and treating constipation. The bifidobacterium bifidum CGMCC NO.13632 is used for preparing pharmaceutical compositions and fermented food for relieving constipation, and has very wide application prospects.

The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of a variety of diseases. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a peptide or functional analogue thereof. Furthermore, the invention provides a method for identifying or obtaining a signaling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing the cell with a peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of a gene transcription factor.

The invention relates to the field of human or veterinary medicine and to the treatment of subjects (be it man or animal) that suffer from iatrogenic disease, i.e., experience problems or complications resulting from a medical treatment. Provided is a method for modulating an iatrogenic event in a subject, the method comprising: providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, provided is the use of an NF-kappaB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of an additional pro-inflammatory cytokine response occurring after an iatrogenic event in a subject.

The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the recurrent upsurges of acute disease, classically known as “relapses” or “exacerbations” or “relapsing/remitting” disease seen in multiple sclerosis. The invention provides a method for modulating a relapsing/remitting disease in a subject suffering therefrom involving providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides the use of an NF-κB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of relapsing/remitting disease as seen with multiple sclerosis.

The invention provides a probiotic composition and a preparation method and application thereof. The probiotic composition comprises raw materials of lactobacillus reuteri, lactobacillus acidophilus and bifidobacterium animalis, wherein the weight ratio of the lactobacillus reuteri to the lactobacillus acidophilus to the bifidobacterium animalis is (1.5-2.5):(0.5-1.5):(0.5-1.5). The colony forming units of the lactobacillus reuteri, the lactobacillus acidophilus or the bifidobacterium animalis in unit weight are the same. The lactobacillus reuteri is preserved in China Center for Type Culture Collection with the preservation number of 209138, and the lactobacillus acidophilus and/or the bifidobacterium animalis preserved in China General Microbiological Culture Collection Center with the preservation number of CGMCC 15210 are/is bifidobacterium animalis BB-115. The probiotic composition can relieve the symptom of slow transit constipation under the condition of low dosage, and can remarkably and effectively regulate gastrointestinal regulatory peptide indexes related to constipation, such as P substance (SP), gastrin (Gas) and vasoactive peptide (VIP).

The invention relates to a salivary gland immunoregulation polypeptide of a dieu cleg and the related genes and the application, belonging to the biomedical field. The immunoregulation polypeptide is a linear polypeptide coded with the Chinese Tabanidae salivary gland immunoregulation polypeptide genes, the sequence of which is glycin- glycin- valine- serine- glycin- valine- serine- aspartic acid- phenylalanine- glutamate- praline- isoleucine- glutamate- valine- serine- glycin- glutamate- aspartic acid- tyrosine- aspartic acid- serine- aspartic acid- glutamate- alanine- aspartic acid- glutamate- aspartic acid- glycin- lysine- alanine. The immunoregulation polypeptide gene is composed of 362 Nucleotides, wherein, the coding mature code salivary gland immunoregulation polypeptide of the dieu cleg is the 115th to the 204th nucleotide. The dieu cleg salivary gland immunoregulation polypeptide is used for inhibiting a plurality of cytokines, which is characterized by simple structure, convenient artificial synthesis and strong antibacterial activity, etc.

The invention discloses an enzyme-labeled immunoassay kit which comprises an antibody pre-coating reaction plate, an enzyme-labeled antibody and luminous substrate liquid, wherein the enzyme-labeled antibody takes SBP (soybean protease) as marker enzyme; the luminous substrate liquid comprises H2O2, luminol and an enhancer; the enhancer consists of MORPH (4-marlene pyridine) and SPTZ (3-(10'-phenothiazinyl) propyl-1-sulfonate). According to the enzyme-labeled immunoassay kit, the SBP is introduced to serve as the marker enzyme; on one hand, the thermal stability of the enzyme is higher than that of HRP (hypothalamic regulatory peptide), and the enzyme has the advantages of wide substrate working range, high heat resistance, high acid-alkaline stability, wide pH application range and the like; on the other hand, when the enhancers MORPH and SPTZ are used for enhancing chemical illumination, a chemical luminous signal is enhanced by nearly 100 times, and the detection sensitivity is greatly improved.

A 3D structure of a hydrogel for supporting cell growth or for use in sustained drug delivery is formed using peptides and/or peptide derivatives that self-assemble via cross-linking into a stiff gel. The hydrogel structure is formed using a method based on 3D printing. A hydrogel precursor is extruded under conditions to generate a hydrogel, by extruding a solution of the peptides into a solution containing cations, whereby the cations enable cross-linking of pi-stacked peptides, or by co-extruding it with the cations, the peptides and cations being mixed only at the point of co-extrusion. The stiffness of the hydrogel can be tuned by adjusting the combination of peptides, either by the selection of peptides or combinations thereof, or the proportions of the combinations, and/or by adjusting the proportion of cations present.

The invention relates to an Odorrana grahami immunomodulation peptide, gene and variant and the application in the pharmacy belonging to the biomedicine field. The Odorrana grahami immunomodulation peptide is a circular peptide with a molecular weight of 1791.12 D and a isoelectric point of 9.84. The whole sequence of the Odorrana grahami immunomodulation peptide is Thr Ser Arg Cys Tyr Ile Gly Tyr Arg Arg Lys Val Val Cys Ser (TSRCYIGYRRKVVCS), wherein the fourth cysteine and 14th cysteine form intramolecular disulfide bond. The code gene is composed of 307 nucleotides, wherein the code mature parts are from 141th to 186th nucleotide. The produced variant is produced by substituting the fourth amino acid in the original sequence of the Odorrana grahami immunomodulation peptide. The artificial synthetic Odorrana grahami immunomodulation peptide and variant thereof has a strong immunomodulation activity and tumor resistance activity and can be used for immunomodulation, tumor treatment and chemotherapeutics. The invention has the advantages such as simple sequence and convenient synthesis.

The invention discloses a solid-phase competition ELISA reagent kit of an antibody for an O-typed foot and mouth disease virus based on a specific monoclonal antibody, which comprises an O-typed foot and mouth disease specific monoclonal antibody marked by HRP (hypothalamic regulatory peptides). The reagent kit of the invention can be used for monitoring a level of the antibody for the O-typed foot and mouth disease virus. By replacing a rabbit antibody, guinea pig antiserum and guinea pig enzyme mark antibody in existing ELISA, the invention simplifies the steps of the ELISA method, improves stability, and greatly shorten detection time from 24 h to 1.5 h or less, thereby breaking through reaction processes for a primary antibody and a second antibody required by original ELISA.

The invention relates to an endogenous regulatory peptide prokineticin 2 (PK2) as a biomarker for psoriasis and its use, and belongs to the field of medical molecular biology. The inventor found that PK2 has a new biological function that promotes wound healing and psoriasis by detecting the expression of PK2 in the blood and skin of psoriasis as a biomarker for detecting the occurrence or development of psoriasis. The invention also relates to the use of PK2 in the treatment or detection of psoriasis and its use in wound healing. The invention has found that PK2 has the function of promoting the occurrence of psoriasis and can detect the occurrence or development of psoriasis by detecting the expression of PK2 in skin and blood of psoriasis. PK2 can be used as the specificity biomarker of the occurrence or development of psoriasis; PK2 as a target has a very good effect on the treatment of psoriasis, and the treatment of psoriasis provides a new target. In addition, the invention also relates to the activity of PK2 to promote wound healing and to provide a new drug template for wound healing.

The invention belongs to the fields of medicine and bioengineering, and discloses an immunoregulation peptide, and a preparation method and application thereof. The amino acid sequence of the immunoregulation is disclosed as SEQ ID NO:1. The immunoregulation peptide has high T lymphopoiesis promoting function, and can be used for preparing T lymphopoiesis promoting drugs.

The invention provides an ELISA (Enzyme-linked Immunosorbent Assay) kit for detecting methotrexate and application thereof. The kit is prepared from the following reagents: a methotrexate coated 96-pore microporous plate, a methotrexate monoclonal antibody, an antibody diluting solution, an HRP (Hypothalamic Regulatory Peptide)-labeled goat anti-mouse secondary antibody, a methotrexate standard product, a washing liquid concentrated solution, a sample diluting solution, a TMB (Tetramethylbenzidine) color-developing solution and a stopping solution. The stable, rapid and simple methotrexate detection kit is obtained through improving the combination of all reagents and improvement on parameters of the reagents; when the ELISA kit is applied, the standard deviation value of the kit is relatively small. The ELISA kit can be used for detecting the plasma drug concentration of patients who utilize the methotrexate with a large dosage and detecting the plasma drug concentration of patients who utilize the methotrexate with a small dosage.

The invention relates to a regulatory peptide and mansonone E in preparation of an improved medicament for treating leukemia and application of the regulatory peptide and the mansonone E. Through model screening, the regulatory peptide capable of promoting the activity of the mansonone E is obtained, the regulatory peptide and the mansonone E are combined to prepare the medicament for treating leukemia. The medicament has the advantages of being small in dosage, moderate in cost, convenient to take, small in side effect and the like.

The invention discloses a composition for removing tumor immunosuppression and application thereof. The composition provided by the invention comprises following (a) to (e) components or coded nucleicacid thereof: (a) IL-15, a mutant thereof or functional fragments thereof; (b) an IL-15 receptor alpha, a mutant thereof or functional fragments thereof; (c) IL-12, a mutant thereof or functional fragments thereof; (d) TGF-beta regulatory peptide, a mutant thereof or functional fragments thereof; and (e) PD1-CD80 fusion protein, a mutant thereof or functional fragments thereof. According to the composition provided by the invention, the immune response of T lymphocytes can be improved synergistically.

The invention provides topical formulations and methods comprising charged bioactive agents complexed with amphipol polymers for dermal and transdermal delivery, optionally further including TJ-modulating peptides.

The present invention concerns peptides and nucleic acids encoding the peptides, and their use for modulating large conductance Ca²⁺ activated K⁺ (BK) channel activity in cells; for treating conditions such as presbycusis (age-related hearing loss), audiogenic seizures, alcohol addiction, cancer, and neurodegenerative disease; and for delivering a cargo moiety to the brain of a subject through the blood-brain barrier.